Your browser doesn't support javascript.
loading
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas.
Amoozgar, Zohreh; Kloepper, Jonas; Ren, Jun; Tay, Rong En; Kazer, Samuel W; Kiner, Evgeny; Krishnan, Shanmugarajan; Posada, Jessica M; Ghosh, Mitrajit; Mamessier, Emilie; Wong, Christina; Ferraro, Gino B; Batista, Ana; Wang, Nancy; Badeaux, Mark; Roberge, Sylvie; Xu, Lei; Huang, Peigen; Shalek, Alex K; Fukumura, Dai; Kim, Hye-Jung; Jain, Rakesh K.
Afiliação
  • Amoozgar Z; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Kloepper J; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Ren J; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Tay RE; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, Boston, MA, USA.
  • Kazer SW; Department of Chemistry, Institute for Medical Engineering & Science, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.
  • Kiner E; Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Krishnan S; Ragon Institute of MGH, MIT & Harvard, Cambridge, MA, USA.
  • Posada JM; Program in Health Sciences and Technology, Harvard Medical School, Boston, MA, USA.
  • Ghosh M; Department of Immunology, Harvard Medical School, Boston, MA, USA.
  • Mamessier E; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Wong C; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Ferraro GB; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Batista A; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Wang N; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Badeaux M; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Roberge S; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Xu L; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Huang P; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Shalek AK; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Fukumura D; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Kim HJ; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA.
  • Jain RK; Department of Chemistry, Institute for Medical Engineering & Science, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.
Nat Commun ; 12(1): 2582, 2021 05 11.
Article em En | MEDLINE | ID: mdl-33976133
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfócitos T Reguladores / Glioblastoma / Resistencia a Medicamentos Antineoplásicos / Proteína Relacionada a TNFR Induzida por Glucocorticoide Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfócitos T Reguladores / Glioblastoma / Resistencia a Medicamentos Antineoplásicos / Proteína Relacionada a TNFR Induzida por Glucocorticoide Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos